Calcimimetics, allosteric activators of the calcium-sensing receptor (CaSR), represent a potential therapeutic approach for conditions involving hypoactive CaSR, such as FHH [1,3]. The gene discussed is CASR; the disease is familial hypocalciuric hypercalcemia.